Health Canada
Symbol of the Government of Canada

Common menu bar links

About Health Canada

Access to Information Requests Completed - July 2014

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the Month of July 2014
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2011-00237 Information regarding Advil Cold and Sinus Nighttime, Drug Identification Number (DIN) 02267632 by Pfizer Consumer Healthcare a division of Pfizer Canada Inc. Disclosed in part 845
A-2012-00481 Documents relating to prescription drug shortages and/or Sandoz. (Nov 1, 2011 to May 31, 2012). Disclosed in part 714
A-2013-00036 Information regarding the medical device REJUVENATE SPT MODULAR STEM and REJUVENATE MODULAR NECK, License numbers 76970 and 76992 by Howmedica Osteonics Corporation. Disclosed in part 382
A-2013-00098 Information regarding Esbriet (pirfenidone) by InterMune Canada Inc. Disclosed in part 723
A-2013-00351 Information regarding the medical devices Stryker Rejuvenate Modular Hip System - Rejuvenate Modular Neck, 0 DEG, 8 DEG, 16 DEG and Rejuvenate SPT Modular Stem - Straight Press-Fit Texture TMFZ. (Jan 1, 2006 to Jun 24, 2013). Disclosed in part 382
A-2013-00409 Reports of all factual accidents and injuries associated with the use of corrective contact lenses (medical device class 2) within Canada. (Jul 13, 2008 to Jul 12, 2013). Disclosed in part 193
A-2013-00777 Documents regarding changes to the medical marihuana regulations, the need for doctors to be the primary points of contact, and the need to establish indoor medical marihuana farms. (Jan 1, 2013 to Oct 1, 2013). Disclosed in part 439
A-2013-00793 Documents pertaining to applications made for licences to produce and distribute medical marihuana in the province of British Columbia under the new Marihuana for Medical Purposes Regulations. No records exist 234
A-2013-01190 List of briefing notes and memos that have been prepared for the minister. (Jan 1, 2014 to Apr 30, 2014). Disclosed in part 34
A-2013-01267 All of the Marihuana for Medical Purposes Regulations application documents submitted by Bedrocan Canada Inc.; Mettrum Ltd; The Peace Naturals Project Inc.; and Tweed Inc. Disclosed in part 989
A-2013-01363 Adverse Reaction Report (AER) for Diclectin. Report numbers: 000497226, 000517681, 000533950, 000541568, 000541619, 000555185. Disclosed in part 23
A-2013-01375 All official policies, guidelines, directive or other guidance documents that govern employees (in force on January 1, 2000), when publishing, reviewing or publically presenting their scientific or technical work, belonging to the occupations classifications AG, BI, CH, DS, EN-ENG/SUR, FO, PC, RO/RCO, SE-REM/RES, SG-SRE, SP, and VM. Disclosed in part 118
A-2013-01382 Information regarding Crestor (Rosuvastatin Calcium), Drug Identification Number (DIN) 02247162, 02247163, 02247164 by AstraZeneca Canada Inc. Disclosed in part 1
A-2013-01408 Adverse Reaction Report (AER) for Taxotere. Report number: E2B_00021387. Disclosed in part 30
A-2013-01425 Information regarding Lansoprazole by Sanis Health Inc. Disclosed in part 113
A-2013-01460 Documents in relation and mentioning radon and real estate transactions. (Jan 1, 2006 to Mar 14, 2014). Disclosed in part 850
A-2013-01489 Documents regarding the Re-evaluation Note REV2013-18: Proposed Approach to Special Reviews. Disclosed in part 25
A-2013-01513 Documents relating to policy and enforcement strategy with respect to the advertising of medical marihuana by licensed producers to the public. (Jan 1, 2013 to Mar 25, 2014). Disclosed in part 42
A-2014-00013 Letter issued prior to January 27, 2012 from Therapeutic Products Directorate to Laboratoire Riva Inc. certifying that the examination of Riva-Latanoprost was complete. Disclosed in part 2
A-2014-00018 Letter issued prior to April 2, 2013 from Therapeutic Products Directorate to Bausch & Lomb Inc. certifying that the examination of BL LATANOPROST (LATANOPROST) was complete. Disclosed in part 2
A-2014-00028 Documents relating to fish health, pest management, and treatments at finfish aquaculture sites #1358 and #1359 in Jordan Bay, Nova Scotia. (May 1, 2013 to Dec 31, 2013). Disclosed in part 10
A-2014-00047 All complaints regarding any homeopathic medicine made by Boiron, marketed to or used by children. (Jan 1, 2007 to Apr 11, 2014). Disclosed in part 11
A-2014-00048 All complaints regarding any homeopathic medicine made by Homeocan, marketed to or used by children. (Jan 1, 2007 to Apr 11, 2014). Disclosed in part 15
A-2014-00049 Names, business addresses, business telephone numbers and business email addresses of all physicians in Canada who have prescribed medical marihuana. (Jan 1, 2012 to May 8, 2014). All exempted 0
A-2014-00070 Following the Wind Turbine Noise and Health Meeting in Denver on August 29, 2013, all documents relied upon that support the public verbal statements made during the "Question & Answer" that: we do not have federal target for wind turbines; that these messages were reflecting the 20% target associated with the wind technology road map but the more accurate representing is that Health Canada or Canada at large speech from the Throne supporting green energy; we don't have a federal target so that was old language and its since been corrected in all of our previous publications. Disclosed in part 43
A-2014-00097 Fiscal year 2011-2012 numbers regarding the amount of grams of dried marihuana that Health Canada (HC) purchased from Prairie Plant Systems (PPS), the amount of money that HC paid per gram for that marihuana and the amount of seeds and their cost that HC purchased from PPS. Disclosed in part 1
A-2014-00114 Adverse Reaction Report (AER) for Cymbalta. Report numbers: 000559816, 000559843, 000559870, 000561556, 000561595, 000565506, 000561916, 000564816, 000560439, 000565967, 000568950, 000569029. Disclosed in part 19
A-2014-00121 Information regarding ACETYLCYSTEINE SOLUTION, Drug Identification Number (DIN) 02243098 by SANDOZ CANADA INCORPORATED. Disclosed in part 9
A-2014-00132 Information regarding PARVOLEX, Drug Identification Number (DIN) 02181460 by MYLAN PHARMACEUTICALS ULC. Disclosed in part 20
A-2014-00163 Contact information for the companies that have been authorized to provide cannabis starting materials to Licensed Producers under the Marihuana for Medical Purposes Regulations. Disclosed in part 1
A-2014-00165 All correspondences with rejected Marihuana for Medical Purposes Regulations licensed producer applicants regarding the reasons for their rejection. (Sep 1 2013 to May 1 2014). Disclosed in part 145
A-2014-00167 Data collected by Health Canada describing holders of a licence to possess medical marihuana. (Jan 1, 2010 to May 21, 2014). Disclosed in part 654
A-2014-00171 Documents regarding consultations with compassion clubs and dispensaries, including any correspondences related to the Marihuana for Medical Purposes Regulations. (May 1, 2012 to May 1, 2014). Disclosed in part 9
A-2014-00202 Adverse Reaction Report (AER) for Plavix. Report number: 000577951. Disclosed in part 7
A-2014-00204 Documents regarding the wind turbine noise and health study and the conduct of noise monitoring at an individual's home. Disclosed in part 38
A-2014-00207 Copy of all statistics or other data detailing the number of phone calls received by the police force to verify certain information, does suspicious individuals hold valid medical marihuana grow operation license. (Jun 14, 2001 to Mar 20, 2014). All disclosed 1
A-2014-00209 Copy of all statistics or other data to show the number of received calls from the police who wanted to check if a suspicious person held a valid medical marihuana grow operation license. (Mar 21, 2014 to May 6, 2014). Disclosed in part 323
A-2014-00214 Documents relating to private group insurance programs where requests have been made to allow Non-Insured Health Benefits (NIHB) to coordinate with the private plan by means of being first payer or where there is proof that the private contract has proven that services NIHB deems eligible were excluded. (Jan 1, 2010 to May 9, 2014). All disclosed 8
A-2014-00222 Documents regarding the number of applications for exemptions received to prescribe methadone for analgesia, the protocol for Canadian physicians to get injectable methadone and procedures relating to compounding methadone. (Jan 1, 2009 to May 14, 2014). All disclosed 5
A-2014-00229 Copies of purchase orders and call-ups for ink and toner supplies. (Jan 31, 2014 to Mar 31, 2014). Disclosed in part 377
A-2014-00232 Most recent report performed by Health Canada at Labs-Mart Inc. in Edmonton, Alberta for their establishment license for testing. (Jul 1, 2012 to May 20, 2014) Disclosed in part 18
A-2014-00237 Copies of all correspondence sent to the medical marihuana program officials by police forces in the cities of Montral and Qubec. (May 8 ,2012 to May 7 2014). No records exist 0
A-2014-00240 All purchase orders for the following Information Technology equipment: printers, copiers, personal computers and notebooks. (Jan 1, 2014 to Mar 31, 2014). Disclosed in part 85
A-2014-00247 All correspondence with the Canadian Home Builders Association that relates to radon. (Jan 1, 2006 to Dec 31, 2007). All disclosed 12
A-2014-00251 All comments on the Re-evaluation note REV2013-18. Disclosed in part 34
A-2014-00253 Document that provides guidance or stipulates how science employees should interact with media in person, in print or electronically. (Jan 1, 2000 to May 20, 2014). All disclosed 199
A-2014-00265 Adverse Reaction Report (AER) for Eloxatin. Report number: E2B_00035832. Disclosed in part 6
A-2014-00291 Documents relating to the number of inspections targeting medical marijuana production licence holders. (Jan 1, 2004 to May 30, 2014). Disclosed in part 3
A-2014-00298 Prescribing Information for the product Prevex (petrolatum), Drug Identification Number (DIN) 00635189. (Jan 1, 2005 to Jun 2, 2014). No records exist 0
A-2014-00299 Prescribing Information for the product Prevex HC Cream 1% (hydrocortisone), Drug Identification Number (DIN) 00804533. (Jan 1, 2005 to Jun 2, 2014). No records exist 0
A-2014-00301 Prescribing Information for the product Prevex B Cream 0.1% (betamethasone valerate), Drug Identification Number (DIN) 00804541. (Jan 1, 2005 to Jun 2, 2014). No records exist 0
A-2014-00339 A listing of the Access to Information requests submitted to Health Canada. (Apr 1, 2014 to Apr 30, 2014). Disclosed in part 12
A-2014-00348 Information pertaining to losses and thefts reports for the following products: Oxycontin, OxyNEO, HYDROMORPH Cantin, Dilaudid, Biphentin, BuTrans, Codeine Contin, MS Contin, MS-IR, Oxy-IR, Targin. (Jul 1, 2013 to Dec 31, 2013). All disclosed 18
A-2014-00349 A listing of the Access to Information requests submitted to Health Canada. (May 1, 2014 to May 31, 2014). Disclosed in part 13
A-2014-00354 All deliverables relating to the following contracts: Golder Associates Ltd (4500311048, 0431), Tetra Tech Sciences International (4500312440, 0431), Kelly Sears Consulting Group Inc. (4500311849, 0491), Students Commission (4500312976, 0491). Disclosed in part 230
A-2014-00358 Costs budgeted by Health Canada for the activities related to the Tobacco Reporting Regulations. (Jan 1, 1998 to Dec 31, 2013. Disclosed in part 44
A-2014-00370 Contracts awarded to SNC Lavalin Group Inc. and/or any of its subsidiaries. (Jan 1, 2004 to Jun 16, 2014). All disclosed 19
A-2014-00373 Adverse Reaction Report (AER) for Avodart. Report numbers: 000376842, 000376891, 000376897. Disclosed in part 12
A-2014-00375 All communications between Health Canada and Privateer Holdings, Inc. (Jan 1, 2013 to Jun 18, 2014). No records exist 0
A-2014-00376 Documents regarding a planned visit to Fort McMurray and/or Fort McKay by the Health Minister, ministerial staff, and department officials in October 2013. All disclosed 2
A-2014-00378 Adverse Reaction Report (AER) for MICARDIS PLUS. Report number: 000197488. Disclosed in part 1
A-2014-00381 All briefing notes and research material prepared for witnesses who spoke before the Standing Senate Committee on Social Affairs, Science and Technology on April 10, and April 30, 2014. All disclosed 95
A-2014-00395 All communications of Environmental and Radiation Health Sciences Directorate with respect to BioInitiative letter (Sage and Carpenter) dated April 16 2014 sent to the Scientific Committee on Emerging and Newly Identified Health Risks regarding their report: "Preliminary Opinion on Potential Health Effects to Electromagnetic Fields 2013". (Apr 16, 2014 to Jun 26, 2014). No records exist 0
A-2014-00398 Documents regarding any fines relating to the Radiation Emitting Devices Act and industrial wind energy facilities No records exist 0
A-2014-00399 Documents regarding an informal policy that supports the implementation and increasing the number of industrial wind energy facilities in Canada. No records exist 0
A-2014-00404 Adverse Reaction Report (AER) for MICARDIS PLUS. Report number: 000304489. Disclosed in part 2
A-2014-00408 All communication and briefing materials concerning health care providers in Vietnam. (Jan 1 2012 to Jul 3, 2014). No records exist 0
A-2014-00410 All documents relating to the number of persons in Canada suffering from unknown diseases. No records exist 0
A-2014-00414 Adverse Reaction Report (AER) for FERAHEME. Report number: 000586654. Disclosed in part 1
A-2014-00422 Adverse Reaction Report (AER) for WinRhoSDF. Report number: 000563586. Disclosed in part 4
A-2014-00473 Document regarding which responsibilities of the Minister of Health, under the Pest Control Products Act, have been delegated to the Pest Management Regulatory Agency. No records exist 0